Original Research
Published on 31 Aug 2023
Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2023.1223020
- 5,602 views
- 19 citations





